Vascular and Neural Complications in Rodent Models of Obesity and Type 2 Diabetes
Presented by Dr. Mark Yorek, Professor of Medicine, University of Iowa and Associate Chief of Staff, Iowa City VA.
Peripheral neuropathy affects around 50% of the diabetic population. Manifestations range from pain, numbness, paresthesia, to ulceration in the extremities, and it is the major cause of non-traumatic amputations. Other than good glycemic control, which is non-effective for subjects with type 2 diabetes, there is no treatment for diabetic peripheral neuropathy. With the prevalence of obesity, type 2 diabetes, and associated complications reaching epidemic levels, there is now a critical need for finding a treatment to preserve, and perhaps restore, nerve function.
Our understanding of peripheral neuropathy, and research into an effective treatment, has come from many years of studying obese and diabetic animal models, primarily rodents. Traditional endpoints in both animal and human studies have been nerve conduction velocity, nerve biopsies, and quantitative sensory testing; however, translation of results from animal studies has not led to an effective treatment.
Watch this Webinar to Learn:
- The challenges in translational modeling of vascular and neural complications in the context of obesity and type 2 diabetes
- How historical rodent models of diabetes have been used to examine diabetic peripheral neuropathy development, progression, and potential treatments (eg., the Zucker and Zucker Diabetic Fatty [ZDF] rats)
- The characterization of peripheral neuropathy and vascular complications in the diabetic ZDSD rat, a more translational rodent model
- The neural complications such as motor and sensory deficits in diabetic ZDSD rats
- The new endpoints that may improve translation of results from the bench to the bedside
About The Presenter:
Dr. Mark Yorek is Professor of Medicine at the University of Iowa and Associate Chief of Staff at the Iowa City Veterans Affairs Medical Center. He is an internationally renowned scientist and has focused a significant portion of his career on understanding obesity- and diabetes-induced neural disease. He is interested in determining the etiology of diabetic peripheral neuropathy (DPN), which has been described to be primarily due to hyperglycemia-induced metabolic defects. Combined with the examination of motor and sensory nerve conduction velocity, and sensory nerve density and function of the cornea and skin, Mark is investigating the etiology of diabetic neuropathy and candidates for treatment.
Mark has published dozens of publications in prestigious journals such as the Journal of Physiology, Journal of Pharmacology, and Diabetes. His research is funded by the NIH and by the VA Medical Center. Mark received his PhD in Biochemistry from the University of North Dakota, followed by a post-doctoral fellowship at the University of Iowa.